NR2E1
ENSG00000112333
Target class
Nuclear receptor
Chromosome
6
- Chemical probe available
- No
- Target name
- NR2E1
- Gene name
- Nuclear receptor subfamily 2 group E member 1
- Gene symbol
- NR2E1
- Previous gene symbols
- TLX
- Protein name
- Nuclear receptor subfamily 2 group E member 1 (Nuclear receptor TLX) (Protein tailless homolog) (Tll) (hTll)
- TLL
- XTLL
- Gene biotype
- Protein coding
- Gene family
- Nuclear receptor subfamily 2 group E
- Target class
- Nuclear receptor
- Target type
- Human gene
- Tissues expressed in
- 10
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 19.98
- Tissue specificity (Gini)
- 0.85
- Tissue specificity (tau)
- 0.892
- KEGG gene identifiers
- hsa:7101
- Protein interaction confidence
- 0.8297
- Protein interaction partners
- 10
- R-HSA-383280
- R-HSA-8943724
- End position
- 108188805
- Start position
- 108166022
- Chromosome
- 6
- Strand
- Forward
- Nucleus .
- Nuclear bodies
- Tissue specificity (tau)
- 0.891977
- Expression inequality (Gini)
- 0.850246
Expression in transcripts per million
- Brain - Caudate (basal ganglia)
- 19.98
- Brain - Anterior cingulate cortex (BA24)
- 17.31
- Brain - Cortex
- 17.05
- Brain - Nucleus accumbens (basal ganglia)
- 16.59
- Brain - Amygdala
- 15.69
Expression in transcripts per million
- Brain - Caudate (basal ganglia)19.98
- Brain - Anterior cingulate cortex (BA24)17.31
- Brain - Cortex17.05
- Brain - Nucleus accumbens (basal ganglia)16.59
- Brain - Amygdala15.69
- Brain - Frontal Cortex (BA9)15.6
- Brain - Putamen (basal ganglia)13.18
- Brain - Hippocampus8.29
- Brain - Hypothalamus5.85
- Brain - Substantia nigra3.48
- Adrenal Gland0.36
- Testis0.15
- Brain - Cerebellum0.13
- Whole Blood0.12
- Brain - Spinal cord (cervical c-1)0.11
- Brain - Cerebellar Hemisphere0.1
- Skin - Sun Exposed (Lower leg)0.06
- Skin - Not Sun Exposed (Suprapubic)0.06
- Pituitary0.06
- Spleen0.04
- Minor Salivary Gland0.03
- Pancreas0.03
- Kidney - Cortex0.02
- Esophagus - Mucosa0.02
- Stomach0.01
And 29 more, listed on the interactive page.
Biological processes
- GO:0007399
Cellular components
- GO:0005654
- GO:0003707
- GO:0005515
- GO:1990837
Related records
Trials (172)
- "AIDA" Protocol (LAP 0493)
- 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
- A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome
- A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel
- A Comparative Study of Adapalene Gel,0.3% Versus Tretinoin Emollient Cream, 0.05% for the Treatment of Photoaging
- A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy
- A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
- A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS
- A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne
- A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris
- A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris
- A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris
- A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- A Study of ATRA in the Treatment of ITP
- A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
- A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
- A Study of Different Use Regimens Using Two Acne Treatments
- A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
- A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea
- A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma